A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States

By afschroeder • October 10, 2025

Cummings AL, Sussell J, Rosettie KL, El Moustaid F, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States. Am J Clin Oncol. 2025 Oct 8. doi: 10.1097/COC.0000000000001248. Epub ahead of print. PMID: 41066159.

Tags: adjuvant treatment, Alectinib, anaplastic lymphoma kinase, Hematology/Oncology, Non-small cell lung cancer, platinum-based chemotherapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Oncofertility patterns after the overturn of Roe v. Wade

Baclig NV, Silverstein J, Shah V, Karlan B, Anand SR, Glaspy JA. Oncofertility patterns after the overturn of Roe v. Wade. J Natl Cancer Inst.[...]

Safety First

Moghanaki D, Gower A. Safety First. Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):18. doi: 10.1016/j.ijrobp.2025.12.009. PMID: 42000358.

Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer

LeVee A, Hennessy MA, Idossa D, Leon-Ferre RA, Nanda R, McArthur H. Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc[...]